Tarsus Pharmaceuticals annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals R&D Spending Growth & History (TARS)
Tarsus Pharmaceuticals's r&d spending was $64.3M for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $64.3M | $10.9M | +20.48% |
| 2024 | 2024-12-31 | $53.4M | $3.1M | +6.11% |
| 2023 | 2023-12-31 | $50.3M | $7.7M | +18.04% |
| 2022 | 2022-12-31 | $42.6M | $912,000 | +2.19% |
| 2021 | 2021-12-31 | $41.7M | $22.9M | +121.57% |
| 2020 | 2020-12-31 | $18.8M | $15.7M | +495.38% |
| 2019 | 2019-12-31 | $3.2M | — | — |
Tarsus Pharmaceuticals quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $31.0M | $15.4M | +98.86% |
| Q1 2026 | 2026-03-31 | $22.4M | $7.9M | +55.12% |
| Q4 2025 | 2025-12-31 | $18.0M | $1.2M | +6.89% |
| Q3 2025 | 2025-09-30 | $16.3M | $4.2M | +34.27% |
| Q2 2025 | 2025-06-30 | $15.6M | $3.3M | +26.58% |
| Q1 2025 | 2025-03-31 | $14.4M | $2.3M | +19.42% |
| Q4 2024 | 2024-12-31 | $16.9M | $3.6M | +26.82% |
| Q3 2024 | 2024-09-30 | $12.1M | $23,000 | +0.19% |
| Q2 2024 | 2024-06-30 | $12.3M | −$227,000 | −1.81% |
| Q1 2024 | 2024-03-31 | $12.1M | −$290,000 | −2.35% |
| Q4 2023 | 2023-12-31 | $13.3M | $3.3M | +32.68% |
| Q3 2023 | 2023-09-30 | $12.1M | $1.2M | +10.93% |
| Q2 2023 | 2023-06-30 | $12.5M | $2.9M | +30.65% |
| Q1 2023 | 2023-03-31 | $12.4M | $275,000 | +2.28% |
| Q4 2022 | 2022-12-31 | $10.0M | $2.0M | +24.76% |
| Q3 2022 | 2022-09-30 | $10.9M | $703,000 | +6.89% |
| Q2 2022 | 2022-06-30 | $9.6M | $2.4M | +33.30% |
| Q1 2022 | 2022-03-31 | $12.1M | −$4.2M | −25.71% |
| Q4 2021 | 2021-12-31 | $8.0M | $452,000 | +5.96% |
| Q3 2021 | 2021-09-30 | $10.2M | $2.2M | +27.76% |
| Q2 2021 | 2021-06-30 | $7.2M | $5.5M | +314.74% |
| Q1 2021 | 2021-03-31 | $16.3M | $14.7M | +975.46% |
| Q4 2020 | 2020-12-31 | $7.6M | — | — |
| Q3 2020 | 2020-09-30 | $8.0M | $7.6M | +1902.76% |
| Q2 2020 | 2020-06-30 | $1.7M | — | — |
| Q1 2020 | 2020-03-31 | $1.5M | — | — |
| Q3 2019 | 2019-09-30 | $399,000 | — | — |
Tarsus Pharmaceuticals r&d spending trends
Over the last five fiscal years, Tarsus Pharmaceuticals's r&d spending increased from $18.8M to $64.3M, a change of $45.5M. The latest reported quarter, Q2 2026, shows $31.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗